{"id":"zolpidem-cr","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Dizziness"},{"rate":"10-15","effect":"Drowsiness/somnolence"},{"rate":"10-15","effect":"Headache"},{"rate":"1-2","effect":"Complex sleep behaviors"},{"rate":"1-2","effect":"Hallucinations"},{"rate":"5-10","effect":"Memory impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zolpidem is a non-benzodiazepine hypnotic (Z-drug) that selectively binds to alpha-1 subunit-containing GABA-A receptors, enhancing the inhibitory effects of GABA and depressing central nervous system activity. The controlled-release formulation provides immediate release for sleep onset followed by sustained release for sleep maintenance throughout the night.","oneSentence":"Zolpidem CR is a sedative-hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:49.711Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia (sleep onset and sleep maintenance)"}]},"trialDetails":[{"nctId":"NCT07420816","phase":"PHASE2","title":"Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder","status":"NOT_YET_RECRUITING","sponsor":"Apsen Farmaceutica S.A.","startDate":"2026-03-26","conditions":"Insomnia, Insomnia Chronic","enrollment":222},{"nctId":"NCT06640023","phase":"NA","title":"The Study in Outpatient Medicine Using Nudges to Improve Sleep","status":"ENROLLING_BY_INVITATION","sponsor":"University of Southern California","startDate":"2024-12-20","conditions":"Inappropriate Prescribing","enrollment":443},{"nctId":"NCT02783729","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2016-05-31","conditions":"Insomnia","enrollment":1006},{"nctId":"NCT02456532","phase":"PHASE4","title":"Safety and Efficacy of Chronic Hypnotic Use 2","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2015-08-05","conditions":"Chronic Insomnia","enrollment":41},{"nctId":"NCT01689909","phase":"PHASE4","title":"Reducing Suicidal Ideation Through Insomnia Treatment","status":"COMPLETED","sponsor":"Augusta University","startDate":"2012-12-06","conditions":"Insomnia, Depression, Suicidal Ideation","enrollment":103},{"nctId":"NCT01485393","phase":"NA","title":"Polysomnographic Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-01","conditions":"Insomnia","enrollment":10},{"nctId":"NCT01685073","phase":"PHASE2, PHASE3","title":"The Role of Sleep in the Treatment of Cannabis Use Disorders","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-09","conditions":"Drug Addiction","enrollment":127},{"nctId":"NCT00814502","phase":"NA","title":"Zolpidem CR and Hospitalized Patients With Dementia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-12","conditions":"Dementia, Alzheimer Disease, Dementia, Vascular","enrollment":20},{"nctId":"NCT01181232","phase":"PHASE4","title":"A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-10","conditions":"Sleep Initiation and Maintenance Disorders, Primary Insomnia","enrollment":132},{"nctId":"NCT01159652","phase":"PHASE4","title":"Hypnotic Medications and Memory: Effect of Drug Exposure During the Night","status":"COMPLETED","sponsor":"St. Luke's Hospital, Chesterfield, Missouri","startDate":"2010-10","conditions":"Sleep, Memory","enrollment":26},{"nctId":"NCT01920334","phase":"PHASE4","title":"Effects of Zolpidem CR® in Sleep and Heart Recovery in Cardiac Intensive Care Unit Patients","status":"UNKNOWN","sponsor":"Associação Fundo de Incentivo à Pesquisa","startDate":"2013-07","conditions":"Acute Coronary Syndrome, Sleep Deprivation","enrollment":100},{"nctId":"NCT01097382","phase":"PHASE4","title":"Sleep Satisfaction and Psychomotor Performance of Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-03","conditions":"Sleep Disorders","enrollment":30},{"nctId":"NCT00956319","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Sleep Initiation and Maintenance Disorders, Primary Insomnia","enrollment":42},{"nctId":"NCT01024192","phase":"PHASE4","title":"Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-11","conditions":"Sleep Disorders","enrollment":135},{"nctId":"NCT00296179","phase":"PHASE4","title":"Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Insomnia","enrollment":372},{"nctId":"NCT00683436","phase":"PHASE2","title":"Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs","status":"TERMINATED","sponsor":"Neurogen Corporation","startDate":"2008-05","conditions":"Primary Insomnia","enrollment":84},{"nctId":"NCT00296790","phase":"PHASE4","title":"Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Insomnia","enrollment":372}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"DRUG INEFFECTIVE"},{"count":4,"reaction":"FALL"},{"count":3,"reaction":"DECREASED APPETITE"},{"count":3,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":3,"reaction":"SEROTONIN SYNDROME"},{"count":2,"reaction":"ABNORMAL BEHAVIOUR"},{"count":2,"reaction":"ANKLE FRACTURE"},{"count":2,"reaction":"CONFUSIONAL STATE"},{"count":2,"reaction":"DEEP VEIN THROMBOSIS"},{"count":2,"reaction":"DELIRIUM"}],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ambian CR","Ambien CR"],"phase":"marketed","status":"active","brandName":"Zolpidem CR","genericName":"Zolpidem CR","companyName":"Henry Ford Health System","companyId":"henry-ford-health-system","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zolpidem CR is a sedative-hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance. Used for Insomnia (sleep onset and sleep maintenance).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-09-02T00:00:00.000Z","mah":"COSETTE","brand_name_local":"AMBIEN CR","application_number":"NDA021774"}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}